- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained...
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously...
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE)...
Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary...
- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treatment-related...
- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade...
Barchart Research What to Expect from IMRX Earnings IMRX Generated May 15, 2026 Current Price $5.16 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Runway Into Twenty-Twenty-Nine:...
Barchart Research What to Expect from IMRX Earnings IMRX Generated May 15, 2026 Current Price $5.16 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Runway Into Twenty-Twenty-Nine:...
Barchart Research What to Expect from IMRX Earnings IMRX Generated May 15, 2026 Current Price $5.16 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Runway Into Twenty-Twenty-Nine:...
- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting - - Pivotal...